IE
BCRX icon

Israel Englander’s BioCryst Pharmaceuticals BCRX Stock Holding History

Israel Englander’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130,000
Closed -$1.24M – 5861
2026
Q1 		$1.24M Buy
+130,000
New +$1.01M ﹤0.01% 4229
2025
Q3 		– Sell
-100,000
Closed -$896K – 6021
2025
Q2 		$896K Buy
+100,000
New +$931K ﹤0.01% 4492
2024
Q4 		– Sell
-101,300
Closed -$770K – 5958
2024
Q3 		$770K Buy
+101,300
New +$770K ﹤0.01% 4472
2024
Q2 		– Sell
-201,200
Closed -$1.02M – 5884
2024
Q1 		$1.02M Sell
201,200
-390,600
-66% -$2.2M ﹤0.01% 4271
2023
Q4 		$3.54M Buy
591,800
+441,600
+294% +$2.56M ﹤0.01% 3096
2023
Q3 		$1.06M Buy
150,200
+49,300
+49% +$354K ﹤0.01% 4146
2023
Q2 		$710K Sell
100,900
-138,400
-58% -$1.11M ﹤0.01% 4303
2023
Q1 		$2M Buy
239,300
+138,600
+138% +$1.33M ﹤0.01% 3447
2022
Q4 		$1.16M Buy
+100,700
New +$1.26M ﹤0.01% 4021
2021
Q2 		– Sell
-40,000
Closed -$407K – 6524
2021
Q1 		$407K Buy
+40,000
New +$412K ﹤0.01% 4995
2020
Q3 		– Sell
-650,000
Closed -$3.1M – 4446
2020
Q2 		$3.1M Buy
650,000
+535,900
+470% +$2.14M ﹤0.01% 2185
2020
Q1 		$228K Buy
114,100
+79,300
+228% +$218K ﹤0.01% 3320
2019
Q4 		$120K Sell
34,800
-176,200
-84% -$443K ﹤0.01% 3992
2019
Q3 		$604K Sell
211,000
-589,000
-74% -$1.83M ﹤0.01% 3133
2019
Q2 		$3.03M Buy
800,000
+400,000
+100% +$2.41M ﹤0.01% 2138
2019
Q1 		$3.26M Buy
+400,000
New +$3.42M ﹤0.01% 2062
2017
Q2 		– Sell
-200,000
Closed -$1.68M – 3452
2017
Q1 		$1.68M Buy
+200,000
New +$1.39M ﹤0.01% 2101
2016
Q4 		– Sell
-300,000
Closed -$1.32M – 3328
2016
Q3 		$1.32M Buy
+300,000
New +$1.2M ﹤0.01% 2138

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Israel Englander's BCRX Position: Q2 2026 in Review

Israel Englander increased its BioCryst Pharmaceuticals (BCRX) stake by 1,708% in Q2 2026, buying an estimated $29M and bringing the position to 3,394,729 shares worth $33.9M. The position accounts for 0.01% of the portfolio, ranked #1177.

Israel Englander first reported a position in BCRX in Q3 2013 and has held it in 51 quarters since. The position peaked at $37.3M in Q2 2023. 316 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Israel Englander held 3,394,729 shares of BioCryst Pharmaceuticals worth $33.9M as of Q2 2026.
  • Israel Englander bought 3,207,008 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $29M.
  • BioCryst Pharmaceuticals made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1177 holding.
  • Israel Englander first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • Israel Englander's BioCryst Pharmaceuticals position peaked at $37.3M in Q2 2023.
  • 316 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.